Bristol Myers scraps Orum's ORM-6151 after Phase 1 data; Korean biotech keeps $100M upfront but forfeits $80M in milestones.
CMS signaled drugmakers joining its Generous Medicaid rebate demo would be exempt from the Globe and Guard Medicare pilots, ...
FDA grants accelerated approval to Ultragenyx's Sanfilippo gene therapy UX111, weeks after the biotech's Angelman Phase 3 ...
CART01; Ori bags $120M deal; Reckitt invests $600M in US; Astellas expands Ireland; Hovione opens NJ facility.
Michael J. Fox Foundation backs Ariadne Bio's AB-300 & launches $2.5B campaign. SK Bio pays $1.8M for 1ST-104. NICE backs ...
Six UK parliamentary committees ask the National Audit Office to probe the cost of the £1B UK-US pharma deal and its NHS ...
CMS expands ACCESS model, a 10-year Medicare pilot using AI/apps for chronic conditions. 160+ orgs enrolled; 17 health plans ...
Therapeutics prices its Nasdaq IPO, 2026's 21st biotech float, to fund a Phase 2/3 trial of immunology drug ipsoprubart.
Marea and North Immunology take reverse-merger routes to Nasdaq with $225M and $180M financings as I&I dealmaking accelerates.
Endpoints Executive Editor Drew Armstrong on why picking the 2026 Endpoints 11 was the hardest yet, and what to expect at the Sept. 24 Boston gala.
Roche's Lunsumio plus Revlimid beat Rituxan/Revlimid in Phase 3 CELESTIMO trial, supporting full FDA approval and second-line ...
Bavarian Nordic has appointed a veteran of Sanofi, AstraZeneca and Pfizer to replace Paul Chaplin as president and CEO.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results